Trellis Vitality review: $150 semaglutide

Trellis Vitality (trellisvitality.com) runs five clinician-guided injectable programs and publishes, for exactly one of them, the cleanest price table we read this month. For the other four it publishes a single number with the words "starting at" in front of it and no ladder behind it. Both halves of that sentence matter, and its own blog gets the second half wrong.

The GLP-1 table is the good one

Semaglutide is $150 a month on a one-month plan, $140 a month on three, and $133 a month on six. Tirzepatide is $199, $189 and $179 across the same three terms. The table is rendered as plain HTML on the program page, behind no quiz and no email gate, labeled "per-month price; longer plans cost less per month", with a second line stating that all dosages are available at the same price.¹

The one-month column is explicitly the month-to-month rung, which is the detail that makes the rest of the table safe to quote. A prepay figure printed as a monthly rate is the error that puts unbuyable numbers at the top of cheapest-first rankings; this table cannot produce it, because the term is named above every column. At $150 for semaglutide, Trellis undercuts most of what sits on our semaglutide wire, and its $199 tirzepatide is a fair rate against the going rate for that molecule.

And then the rest of the shelf

NAD+ is Trellis's flagship. Its page says treatment plans start at $129 a month. That is the entire pricing disclosure. Glutathione starts at $93, lipo-MIC with B12 at $130, tesamorelin at $299 — four programs, four single figures, no rung table anywhere.¹ We pulled the site's build output, the rendered pages and the intake payload behind the NAD+ program; the intake carries store theming and questionnaire metadata and no product prices at all.

So we file those four as "from $129, full ladder not published" and we will not print any of them as a monthly rate. Here is why that matters rather than being pedantic: on the one program where Trellis does publish a ladder, the six-month rung sits about 12 per cent below the one-month rung. If the same structure applies to NAD+, then $129 is the six-month rung and the month-to-month price is higher. That is an inference, not an observation, and an inference is not a price.

The claim its own blog makes

Trellis's blog post on NAD+ injection cost, updated in July 2026, states twice that Trellis publishes its complete pricing on the program page. It does not. The program page publishes one "starting at" figure, which is the specific thing that post criticizes competitors for doing. We are not calling that dishonest — marketing copy drifts from product reality constantly, and this reads like a page written against an intention rather than against the site. But a desk that advertises its pricing transparency is inviting exactly this check, and it fails it on four of its five programs.

The same page furniture carries a star rating, a current-patient count and an average annual savings figure, none of which is sourced anywhere on the site. This desk does not repeat unsourced marketing statistics, so we have not printed them.

Who is behind it

The medicine is practiced by Arora Health & Aesthetics, LLC, medical director Dr. Sean Arora, NPI 1841729449 — active in the federal NPPES registry, family medicine.² The pharmacy is VialsRX, a state-licensed compounding pharmacy in Houston, and Trellis names it in its own machine-readable site file rather than making you hunt for it. Naming a pharmacy at all puts Trellis in the minority of the desks we read this month, and it is the check our five-minute provider checklist puts second. Intake and billing run on Bask Health. The site claims board-certified physicians in all 50 states.

What is not published is the corporate entity. The terms page runs to about three kilobytes of text and never names an LLC or a corporation, so there is no filing name to look up. For a desk this forthcoming about its pharmacy, that is an odd omission.

The overlap with The Edit

Arora Health & Aesthetics and Dr. Arora also stand behind The Edit. Trellis uses a different pharmacy, sells a different catalog and charges materially less for both molecules, so these are two real products rather than one product with two skins. But they run on the same clinical group, and treating them as independent second opinions in the same ranking would be wrong. If Trellis declines you, The Edit is not a different clinician.

Fees and the exit

Trellis advertises no membership and no consult cost, and a free assessment to start. We could not corroborate any of that in a terms document, because the terms document barely exists. There is no evidence of a fee charged regardless of outcome, and no evidence of the opposite either — the disclosure is thin rather than adverse. On the programs where the ladder is published, the shortest term is one month, so the exit is a month away rather than a contract away, which is more than Rehydra+ can say.

The regulatory screen

The trading name, the medical group and the pharmacy all returned zero company-column matches in the FDA's live warning-letter index in August 2026, against a positive control that correctly returned a known February 2026 letter for an unrelated telehealth seller.³ Its LegitScript seal resolves to a real certification record; we checked by probing the seal image itself, because the certification page returns a page for domains that were never certified.

Where it lands

For semaglutide and tirzepatide, Trellis is one of the two or three cleanest reads in this batch: a real table, a named pharmacy, a verifiable prescriber, a month-to-month column that says so. For NAD+, glutathione, lipo-MIC or tesamorelin, it is a desk you cannot price without starting an intake, and you should treat every figure it publishes for those four as a floor rather than a rate. The rest of the research library is where to go next if you want the evidence behind the molecules themselves.